含氨基乙烯半胱氨酸核糖体肽的生物合成与化学合成

doi:10.12211/2096-8280.2024-037

合成生物学 ›› 2024, Vol. 5 ›› Issue (5): 981-996.DOI: 10.12211/2096-8280.2024-037

含氨基乙烯半胱氨酸核糖体肽的生物合成与化学合成

谢向前¹, 郭雯¹, 王欢¹, 李进¹^,²

^1.南京大学化学与生物医药创新研究院，配位化学国家重点实验室，南京大学化学化工学院，江苏省先进有机材料重点实验室，江苏南京 210093
^2.南京药石科技股份有限公司，江苏南京 210032

收稿日期:2024-04-17 修回日期:2024-07-26 出版日期:2024-10-31 发布日期:2024-11-20
通讯作者: 李进
作者简介:谢向前（1997—），男，博士研究生。研究方向为天然产物的生物合成等。E-mail：dg21240123@smail.nju.edu.cn
李进（1987—），男，研究员，执行总监。研究方向为非天然氨基酸分子砌块的合成与应用。E-mail：li_jin@PharmaBlock.com
基金资助:
国家自然科学基金(22325702)

Biosynthesis and chemical synthesis of ribosomally synthesized and post-translationally modified peptides containing aminovinyl cysteine

Xiangqian XIE¹, Wen GUO¹, Huan WANG¹, Jin LI¹^,²

^1.State Key Laboratory of Coordination Chemistry，Chemistry and Biomedicine Innovation Center of Nanjing University，Jiangsu Key Laboratory of Advanced Organic Materials，School of Chemistry and Chemical Engineering，Nanjing University，Nanjing 210093，Jiangsu，China
^2.PharmaBlock Sciences （Nanjing），INC. ，Nanjing 210032，Jiangsu，China

Received:2024-04-17 Revised:2024-07-26 Online:2024-10-31 Published:2024-11-20
Contact: Jin LI

摘要/Abstract

摘要：

核糖体肽是一类拥有化学结构和生物活性多样性的多肽天然产物家族，在药物开发方面具有巨大的发展潜力。氨基乙烯半胱氨酸（AviCys）是部分核糖体肽类天然产物中存在的一种特殊C末端交联结构单元。含有AviCys单元的核糖体肽类天然环肽往往具有优良的抗菌或抗肿瘤活性，且AviCys大环结构对其生物活性至关重要。本文围绕此类天然环肽的生物合成和化学合成进行了总结：①羊毛硫肽、lipolanthines、linaridins和thioamitides四类核糖体肽天然产物中AviCys结构单元的生物合成研究进展，主要包括C末端半胱氨酸的氧化脱羧反应，丝氨酸/苏氨酸或半胱氨酸脱水或脱硫反应，以及AviCys环化反应；②针对含AviCys结构单元环肽的化学合成方法，包括自由基硫醇-炔偶联、氧化脱羧/脱羰、酰胺与缩醛缩合等。本综述同时对相关研究中存在的若干挑战和尚待解决的问题进行了梳理和总结，包括生物合成过程中尚未得到深入解析的环化步骤、化学合成中尚未解决的立体选择性和化学兼容性等。综上，对含AviCys结构单元天然环肽的生物合成途径全面解析及化学合成方法的开发，有望为此类生物功能环肽及其衍生物的制备与生物工程改造奠定基础，推动该类功能环肽在生命科学和药物科学领域的应用。

关键词: 核糖体肽, 天然产物, 氨基乙烯半胱氨酸, 生物合成, 化学合成

Abstract:

Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a major class of peptide natural products that often contain noncanonical amino acids and structural motifs with promising potential as drug leads. One unique structural unit found in RiPPs is the C-terminal S-[(Z)-2-aminoethenyl]-D-cysteine (AviCys) or (2S,3S)-S-[(Z)-2-aminoethenyl]-3-methyl-D-cysteine (AviMeCys). Avi(Me)Cys-containing RiPPs usually exhibit potent antimicrobial or anticancer activities, which strictly require the presence of the C-terminal AviCys motifs. Despite the potential of Avi(Me)Cys-containing RiPPs as drug leads, lack of synthetic methods and biosynthetic systems to access these type of cyclic peptides impede the application of Avi(Me)Cys-containing peptides in medicinal chemistry. In this review, we summarize the current understanding of the biosynthesis of Avi(Me)Cys-containing peptides and the progress made in the development of chemical methods to synthesize Avi(Me)Cys motifs and derivatives. This review contains two following major sections: ① The biosynthetic process of Avi(Me)Cys motifs in the different families of Avi(Me)Cys-containing RiPPs, including lanthipeptides, lipolanthines, linaridins and thioamitides, are introduced with three essential enzymatic steps: first, a cysteine decarboxylase oxidatively decarboxylated the C-terminal cysteine, generating a highly reactive enethiol; subsequently, distinct enzymes catalyze the dehydration of a serine/threonine (Ser/Thr) residue or the dethiolation of a Cys residue in the precursor peptide by incorporating a dehydroalanine (Dha) or dehydrobutyrine (Dhb) residue; finally, a putative cyclase catalyzes the Michael-type addition between the enethiol group and a Dha/Dhb residue to yield the Avi(Me)Cys motif. Detailed enzymatic investigation of these biosynthetic steps are introduced. ② The chemical synthesis of the Avi(Me)Cys building block and their analogues via diverse synthetic methodology, including the radical thiol-yne coupling, the oxidative decarboxylation/decarbonylation, and the condensation of amides with acetals. Overall, further elucidation of the complete biosynthetic pathway for Avi(Me)Cys motifs in related RiPPs, along with advancements in the chemical synthesis of Avi(Me)Cys-containing natural product peptides, will facilitate the effective utilization of these bioactive peptide natural products.

Key words: RiPPs, natural products, aminovinyl cysteine, biosynthesis, chemical synthesis

中图分类号:

Q936

谢向前, 郭雯, 王欢, 李进. 含氨基乙烯半胱氨酸核糖体肽的生物合成与化学合成[J]. 合成生物学, 2024, 5(5): 981-996.

Xiangqian XIE, Wen GUO, Huan WANG, Jin LI. Biosynthesis and chemical synthesis of ribosomally synthesized and post-translationally modified peptides containing aminovinyl cysteine[J]. Synthetic Biology Journal, 2024, 5(5): 981-996.

图/表 10

表1 含有Avi（Me）Cys结构单元天然产物的产生菌株及其生物活性

Table 1 Bacterial producers and bioactivity of Avi(Me)Cys-containing peptides

亚家族	天然产物	产生菌株	生物活性
羊毛硫肽	Microbisporicins^[8]	Microbispora ATCC PTA-5024	对MRSA、Streptococcus pneumoniae等有抗菌活性
	Epidermin^[9]	Staphylococcus epidermidis Tü 3298	对Mariniluteicoccus flavus、Staphylococcus simulans等有抗菌活性
	Mersacidin^[10]	Bacillus amyloliquefaciens	对Staphylococcus aureus、MRSA等有抗菌活性
	Lexapeptide^[11]	Streptomyces rochei Sal35	对MRSA、MRSE等有抗菌活性
Lipolanthines	Microvionin^[12]	Microbacterium arborescens	对MRSA、Streptococcus pneumoniae等有抗菌活性
	Nocavionin^[12]	Nocardia terpenica	尚未报道
	Goadvionins^[13]	Streptomyces sp. TP-A0584	对Staphylococcus aureus、Bacillus subtilis等有抗菌活性
	Lipoavitides^[14]	Streptomyces sp. NRRL S-1521	溶血活性
Linaridins	Cypemycin^[15]	Streptomyces sp. OH-4156	对P388白血病细胞有细胞毒性，对Micrococcus luteus等有抗菌活性
	Salinipeptins^[16]	Streptomyces sp. strain GSL-6C	对Streptococcus pyogenes M1T1等有抗菌作用
Thioamitides	Thioviridamide^[7]	Streptomyces olivoviridis NA005001	诱导细胞凋亡
	Thioholgamides^[17]	Streptomyces malayseiense	抗增殖活性、细胞毒性

图1 含Avi（Me）Cys结构的核糖体肽中常见的结构单元

Fig. 1 Chemical structures of the noncanonical amino acids commonly found in Avi(Me)Cys-containing peptides

图2 第Ⅰ～Ⅴ类羊毛硫肽合成酶的结构域组成

Fig. 2 Domain organization of the enzyme(s) that produce lanthipeptides from Class Ⅰ–Ⅴ

图3 含Avi（Me）Cys结构的代表性核糖体肽天然产物

Fig. 3 Chemical structures of representative ribosomal peptide natural products containing Avi(Me)Cys

图4 由LanD催化的C末端半胱氨酸的氧化脱羧

Fig. 4 Oxidative decarboxylation of a C-terminal cysteine-bearing peptide, catalyzed by LanD

图5 通过谷氨酰化或磷酸化中间体形成 Dha/Dhb

Fig. 5 Formation of Dha/Dhb residues through glutamylated or phosphorylated intermediates

图6 microvionin中avionin结构可能的生物合成途径

Fig. 6 Proposed biosynthetic pathway of the avionin unit in microvionin

图7 自由基硫醇-炔偶联的可能机制（a）和半胱氨酸衍生物与炔酰胺的自由基硫醇-炔偶联反应（b）AIBN—2，2′-偶氮二（2-甲基丙腈）；Cbz—羧基苄基；PMB—对甲氧基苄基

Fig. 7 Postulated mechanism for radical thiol-yne reaction for the synthesis of an AviCys derivative by Castle et al. (a) and Attempted radical thiol-yne coupling of cysteine derivative with ynamides by Castle et al. (b)AIBN—2,2′-Azobis(2-methylpropionitrile); Cbz—Carboxybenzyl; PMB—para-Methoxybenzyl

图8 硫酯的脱羰基反应（a），氧化脱羧/脱羰反应构建mersacidin的C末端环（b）和氧化脱羧/脱羰反应的可能机制（c）Ni（COD）2—双（1，5-环辛二烯）镍（0）；CuTC—硫代苯-2-甲酸铜（Ⅰ）；Cbz—羧基苄基

Fig. 8 Decarbonylation of thioesters to give AviMeCys derivatives and building blocks (a). Oxidative decarboxylation/decarbonylation of the C-terminal ring of mersacidin by VanNieuwenhze et al (b). Postulated mechanism of oxidative decarboxylation/decarbonylation (c)Ni(COD)2—Bis(1,5-cyclooctadiene)nickel(0); CuTC—Copper(Ⅰ) Thiophene-2-carboxylate; Cbz—Carboxybenzyl

图9 通过乙酰胺与缩醛 22 缩合合成 AviCys 衍生物（a）和通过醛25与酰胺（Tcp）Val-NH2缩合及肽链延伸、内酰胺化合成cypemycin中的AviCys结构（b）Pht—邻苯二甲酰亚胺；Tcp—3，4，5，6-四氯邻苯二甲酰亚胺

Fig. 9 Synthesis of AviCys derivativesa via condensation of acetamide upon acetal 22 in the presence of a mild lewis acid (a) and Synthesis of the AviCys-containing ring of cypemycin via condensation of aldehyde 25 with amide (Tcp) Val-NH2, followed by elongation of the peptide chain and lactamization to give 29 in 4.6% yield from 25 (b)Pht—Phthalimide; Tcp—3,4,5,6-Tetrachlorophthalimide

参考文献 68

1	ARNISON P G, BIBB M J, BIERBAUM G, et al. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature[J]. Natural Product Reports, 2013, 30(1): 108-160.
2	MONTALBÁN-LÓPEZ M, SCOTT T A, RAMESH S, et al. New developments in RiPP discovery, enzymology and engineering[J]. Natural Product Reports, 2021, 38(1): 130-239.
3	SCHEIDLER C M, KICK L M, SCHNEIDER S. Ribosomal peptides and small proteins on the rise[J]. Chembiochem, 2019, 20(12): 1479-1486.
4	CHENG B T, XUE Y Q, DUAN Y T, et al. Enzymatic formation of an aminovinyl cysteine residue in ribosomal peptide natural products[J]. ChemPlusChem, 2024, 89(6): e202400047.
5	GRANT-MACKIE E S, WILLIAMS E T, HARRIS P W R, et al. Aminovinyl cysteine containing peptides: a unique motif that imparts key biological activity[J]. JACS Au, 2021, 1(10): 1527-1540.
6	DISCHINGER J, BASI CHIPALU S, BIERBAUM G. Lantibiotics: promising candidates for future applications in health care[J]. International Journal of Medical Microbiology, 2014, 304(1): 51-62.
7	HAYAKAWA Y, SASAKI K, ADACHI H, et al. Thioviridamide, a novel apoptosis inducer in transformed cells from Streptomyces olivoviridis [J]. Journal of Antibiotics, 2006, 59(1): 1-5.
8	CASTIGLIONE F, LAZZARINI A, CARRANO L, et al. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens[J]. Chemistry & Biology, 2008, 15(1): 22-31.
9	ALLGAIER H, JUNG G, WERNER R G, et al. Epidermin: sequencing of a heterodetic tetracyclic 21-peptide amide antibiotic[J]. European Journal of Biochemistry, 1986, 160(1): 9-22.
10	CHATTERJEE S, CHATTERJEE S, LAD S J, et al. Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization[J]. Journal of Antibiotics, 1992, 45(6): 832-838.
11	XU M, ZHANG F, CHENG Z, et al. Functional genome mining reveals a classⅤlanthipeptide containing a D-amino acid introduced by an F₄₂₀H₂-dependent reductase[J]. Angewandte Chemie International Edition, 2020, 59(41): 18029-18035.
12	WIEBACH V, MAINZ A, SIEGERT M A J, et al. The anti-staphylococcal lipolanthines are ribosomally synthesized lipopeptides[J]. Nature Chemical Biology, 2018, 14(7): 652-654.
13	KOZAKAI R, ONO T, HOSHINO S, et al. Acyltransferase that catalyses the condensation of polyketide and peptide moieties of goadvionin hybrid lipopeptides[J]. Nature Chemistry, 2020, 12(9): 869-877.
14	REN H Q, HUANG C S, PAN Y W, et al. Non-modular fatty acid synthases yield distinct N-terminal acylation in ribosomal peptides[J/OL]. Nature Chemistry, 2024. (2024-03-25)[2024-04-01]. .
15	KOMIYAMA K, OTOGURO K, SEGAWA T, et al. A new antibiotic, cypemycin. Taxonomy, fermentation, isolation and biological characteristics[J]. Journal of Antibiotics, 1993, 46(11): 1666-1671.
16	SHANG Z, WINTER J M, KAUFFMAN C A, et al. Salinipeptins: integrated genomic and chemical approaches reveal unusual D-amino acid-containing ribosomally synthesized and post-translationally modified peptides (RiPPs) from a great salt lake Streptomyces sp[J]. ACS Chemical Biology, 2019, 14(3): 415-425.
17	DAHLEM C, SIOW W X, LOPATNIUK M, et al. Thioholgamide A, a new anti-proliferative anti-tumor agent, modulates macrophage polarization and metabolism[J]. Cancers, 2020, 12(5): 1288.
18	ONGEY E L, NEUBAUER P. Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical production[J]. Microbial Cell Factories, 2016, 15: 97.
19	ONGEY E L, YASSI H, PFLUGMACHER S, et al. Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies[J]. Biotechnology Letters, 2017, 39(4): 473-482.
20	BANERJEE B, LITVINOV D N, KANG J, et al. Stereoselective additions of thiyl radicals to terminal ynamides[J]. Organic Letters, 2010, 12(11): 2650-2652.
21	GARCÍA-REYNAGA P, CARRILLO A K, VANNIEUWENHZE M S. Decarbonylative approach to the synthesis of enamides from amino acids: stereoselective synthesis of the (Z)- aminovinyl-D-cysteine unit of mersacidin[J]. Organic Letters, 2012, 14(4): 1030-1033.
22	CARRILLO A K, VANNIEUWENHZE M S. Synthesis of the AviMeCys-containing D-ring of mersacidin[J]. Organic Letters, 2012, 14(4): 1034-1037.
23	LUTZ J A, SUBASINGHEGE DON V, KUMAR R, et al. Influence of sulfur on acid-mediated enamide formation[J]. Organic Letters, 2017, 19(19): 5146-5149.
24	LUTZ J A, TAYLOR C M. Synthesis of the aminovinylcysteine-containing C-terminal macrocycle of the linaridins[J]. Organic Letters, 2020, 22(5): 1874-1877.
25	KUMASHIRO M, OHSAWA K, DOI T. Photocatalyzed oxidative decarboxylation forming aminovinylcysteine containing peptides[J]. Catalysts, 2022, 12(12): 1615.
26	ROGERS L A, WHITTIER E O. Limiting factors in the lactic fermentation[J]. Journal of Bacteriology, 1928, 16(4): 211-229.
27	REPKA L M, CHEKAN J R, NAIR S K, et al. Mechanistic understanding of lanthipeptide biosynthetic enzymes[J]. Chemical Reviews, 2017, 117(8): 5457-5520.
28	GENG M X, SMITH L. Improving the attrition rate of Lanthipeptide discovery for commercial applications[J]. Expert Opinion on Drug Discovery, 2018, 13(2): 155-167.
29	BAKHTIARY A, COCHRANE S A, MERCIER P, et al. Insights into the mechanism of action of the two-peptide lantibiotic lacticin 3147[J]. Journal of the American Chemical Society, 2017, 139(49): 17803-17810.
30	BREUKINK E, DE KRUIJFF B. Lipid Ⅱ as a target for antibiotics[J]. Nature Reviews Drug Discovery, 2006, 5(4): 321-323.
31	BRÖTZ H, JOSTEN M, WIEDEMANN I, et al. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics[J]. Molecular Microbiology, 1998, 30(2): 317-327.
32	HSU S T D, BREUKINK E, TISCHENKO E, et al. The nisin-lipid Ⅱ complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics[J]. Nature Structural & Molecular Biology, 2004, 11(10): 963-967.
33	DICKMAN R, MITCHELL S A, FIGUEIREDO A M, et al. Molecular recognition of lipid Ⅱ by lantibiotics: synthesis and conformational studies of analogues of nisin and mutacin rings A and B[J]. Journal of Organic Chemistry, 2019, 84(18): 11493-11512.
34	POKHREL R, BHATTARAI N, BARAL P, et al. Molecular mechanisms of pore formation and membrane disruption by the antimicrobial lantibiotic peptide Mutacin 1140[J]. Physical Chemistry Chemical Physics, 2019, 21(23): 12530-12539.
35	HSU S T D, BREUKINK E, BIERBAUM G, et al. NMR study of mersacidin and lipid Ⅱ interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity[J]. Journal of Biological Chemistry, 2003, 278(15): 13110-13117.
36	KRUSZEWSKA D, SAHL H G, BIERBAUM G, et al. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model[J]. Journal of Antimicrobial Chemotherapy, 2004, 54(3): 648-653.
37	BLAESSE M, KUPKE T, HUBER R, et al. Crystal structure of the peptidyl-cysteine decarboxylase EpiD complexed with a pentapeptide substrate[J]. EMBO Journal, 2000, 19(23): 6299-6310.
38	BLAESSE M, KUPKE T, HUBER R, et al. Structure of MrsD, an FAD-binding protein of the HFCD family[J]. Acta Crystallographica Section D, Biological Crystallography, 2003, 59(Pt 8): 1414-1421.
39	MO T L, YUAN H, WANG F T, et al. Convergent evolution of the Cys decarboxylases involved in aminovinyl-cysteine (AviCys) biosynthesis[J]. FEBS Letters, 2019, 593(6): 573-580.
40	SIT C S, YOGANATHAN S, VEDERAS J C. Biosynthesis of aminovinyl-cysteine-containing peptides and its application in the production of potential drug candidates[J]. Accounts of Chemical Research, 2011, 44(4): 261-268.
41	LU J X, LI J, WU Y, et al. Characterization of the FMN-dependent cysteine decarboxylase from thioviridamide biosynthesis[J]. Organic Letters, 2019, 21(12): 4676-4679.
42	KUPKE T, KEMPTER C, JUNG G, et al. Oxidative decarboxylation of peptides catalyzed by flavoprotein EpiD. Determination of substrate specificity using peptide libraries and neutral loss mass spectrometry[J]. Journal of Biological Chemistry, 1995, 270(19): 11282-11289.
43	XIA Y Z, YI Y C, SHI Y, et al. Enzymatic generation of thioaldehyde motifs by flavin-dependent cysteine decarboxylases for peptide bioconjugation and macrocyclization[J]. Organic Letters, 2023, 25(32): 6035-6039.
44	WANG S, WU K W, TANG Y J, et al. Dehydroamino acid residues in bioactive natural products[J]. Natural Product Reports, 2024, 41(2): 273-297.
45	BOTHWELL I R, COGAN D P, KIM T, et al. Characterization of glutamyl-tRNA-dependent dehydratases using nonreactive substrate mimics[J]. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(35): 17245-17250.
46	CHATTERJEE C, MILLER L M, LEUNG Y L, et al. Lacticin 481 synthetase phosphorylates its substrate during lantibiotic production[J]. Journal of the American Chemical Society, 2005, 127(44): 15332-15333.
47	DONG S H, TANG W X, LUKK T, et al. The enterococcal cytolysin synthetase has an unanticipated lipid kinase fold[J]. eLife, 2015, 4: e07607.
48	HUANG S Q, WANG Y, CAI C X, et al. Discovery of a unique structural motif in lanthipeptide synthetases for substrate binding and interdomain interactions[J]. Angewandte Chemie International Edition, 2022, 61(45): e202211382.
49	HERNANDEZ GARCIA A, NAIR S K. Structure and function of a class Ⅲ metal-independent lanthipeptide synthetase[J]. ACS Central Science, 2023, 9(10): 1944-1956.
50	SIGURDSSON A, MARTINS B M, DÜTTMANN S A, et al. Discovery of the lanthipeptide curvocidin and structural insights into its trifunctional synthetase CuvL[J]. Angewandte Chemie International Edition, 2023, 62(23): e202302490.
51	LIANG H Q, LOPEZ I J, SÁNCHEZ-HIDALGO M, et al. Mechanistic studies on dehydration in class Ⅴ lanthipeptides[J]. ACS Chemical Biology, 2022, 17(9): 2519-2527.
52	XUE Y Q, LI M, HU L, et al. Mechanistic investigations into the catalytic mode of a dehydratase complex involved in the biosynthesis of lantibiotic cacaoidin[J]. Chinese Journal of Chemistry, 2023, 41(24): 3579-3586.
53	LI B, YU J P, BRUNZELLE J S, et al. Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis[J]. Science, 2006, 311(5766): 1464-1467.
54	MUKHERJEE S, VAN DER DONK W A. Mechanistic studies on the substrate-tolerant lanthipeptide synthetase ProcM[J]. Journal of the American Chemical Society, 2014, 136(29): 10450-10459.
55	THIBODEAUX C J, HA T, VAN DER DONK W A. A price to pay for relaxed substrate specificity: a comparative kinetic analysis of the class Ⅱ lanthipeptide synthetases ProcM and HalM2[J]. Journal of the American Chemical Society, 2014, 136(50): 17513-17529.
56	YANG X, VAN DER DONK W A. Michael-type cyclizations in lantibiotic biosynthesis are reversible[J]. ACS Chemical Biology, 2015, 10(5): 1234-1238.
57	YU Y, MUKHERJEE S, VAN DER DONK W A. Product formation by the promiscuous lanthipeptide synthetase ProcM is under kinetic control[J]. Journal of the American Chemical Society, 2015, 137(15): 5140-5148.
58	LU J X, LI Y Q, BAI Z B, et al. Enzymatic macrocyclization of ribosomally synthesized and posttranslational modified peptides via C—S and C—C bond formation[J]. Natural Product Reports, 2021, 38(5): 981-992.
59	WIEBACH V, MAINZ A, SCHNEGOTZKI R, et al. An amphipathic alpha-helix guides maturation of the ribosomally-synthesized lipolanthines[J]. Angewandte Chemie International Edition, 2020, 59(38): 16777-16785.
60	CHU L X, CHENG J D, ZHOU C Z, et al. Hijacking a linaridin biosynthetic intermediate for lanthipeptide production[J]. ACS Chemical Biology, 2022, 17(11): 3198-3206.
61	XUE Y Q, WANG X F, LIU W. Reconstitution of the linaridin pathway provides access to the family-determining activity of two membrane-associated proteins in the formation of structurally underestimated cypemycin[J]. Journal of the American Chemical Society, 2023, 145(12): 7040-7047.
62	CLAESEN J, BIBB M. Genome mining and genetic analysis of cypemycin biosynthesis reveal an unusual class of posttranslationally modified peptides[J]. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(37): 16297-16302.
63	CLAESEN J, BIBB M J. Biosynthesis and regulation of grisemycin, a new member of the linaridin family of ribosomally synthesized peptides produced by Streptomyces griseus IFO 13350[J]. Journal of Bacteriology, 2011, 193(10): 2510-2516.
64	WANG F T, WEI W Q, ZHAO J F, et al. Genome mining and biosynthesis study of a type B linaridin reveals a highly versatile α-N-methyltransferase[J]. CCS Chemistry, 2020, 3(3): 1049-1057.
65	GEORGIOU M A, DOMMARAJU S R, GUO X R, et al. Bioinformatic and reactivity-based discovery of linaridins[J]. ACS Chemical Biology, 2020, 15(11): 2976-2985.
66	LU J X, WU Y, LI Y Q, et al. The utilization of lanthipeptide synthetases is a general strategy for the biosynthesis of 2-aminovinyl-cysteine motifs in thioamitides[J]. Angewandte Chemie International Edition, 2021, 60(4): 1951-1958.
67	DENOËL T, LEMAIRE C, LUXEN A. Progress in lanthionine and protected lanthionine synthesis[J]. Chemistry, 2018, 24(58): 15421-15441.
68	JIMÉNEZ J C, BAYÓ N, CHAVARRÍA B, et al. Synthesis of peptides containing α,β-didehydroamino acids. Scope and limitations[J]. Letters in Peptide Science, 2002, 9(2): 135-141.

[1]	郑皓天, 李朝风, 刘良叙, 王嘉伟, 李恒润, 倪俊. 负碳人工光合群落的设计、优化与应用[J]. 合成生物学, 2024, 5(5): 1189-1210.
[2]	程晓雷, 刘天罡, 陶慧. 萜类化合物的非常规生物合成研究进展[J]. 合成生物学, 2024, 5(5): 1050-1071.
[3]	杨皓然, 叶发荣, 黄平, 王平. 糖蛋白合成的研究进展[J]. 合成生物学, 2024, 5(5): 1072-1101.
[4]	程中玉, 李付琸. 基于P450选择性氧化的天然产物化学-酶法合成进展[J]. 合成生物学, 2024, 5(5): 960-980.
[5]	刘子健, 穆柏杨, 段志强, 王璇, 陆晓杰. 与核酸兼容的化学反应开发进展[J]. 合成生物学, 2024, 5(5): 1102-1124.
[6]	张守祺, 王涛, 孔尧, 邹家胜, 刘元宁, 徐正仁. 天然产物的化学-酶法合成：方法与策略的演进[J]. 合成生物学, 2024, 5(5): 913-940.
[7]	汤志军, 胡友财, 刘文. 酶促4+2和2+2环加成反应：区域与立体选择性的理解与应用[J]. 合成生物学, 2024, 5(3): 401-407.
[8]	张俊, 金诗雪, 云倩, 瞿旭东. 聚酮化合物非天然延伸单元的生物合成与结构改造应用[J]. 合成生物学, 2024, 5(3): 561-570.
[9]	陈锡玮, 张华然, 邹懿. 真菌源非核糖体肽类药物生物合成及代谢工程[J]. 合成生物学, 2024, 5(3): 571-592.
[10]	虞旭昶, 吴辉, 李雷. 文库构建与基因簇靶向筛选驱动的微生物天然产物高效发现[J]. 合成生物学, 2024, 5(3): 492-506.
[11]	冯金, 潘海学, 唐功利. 近十年天然产物药物的生物合成研究进展[J]. 合成生物学, 2024, 5(3): 408-446.
[12]	奚萌宇, 胡逸灵, 顾玉诚, 戈惠明. 基因组挖掘指导天然药物分子的发现[J]. 合成生物学, 2024, 5(3): 447-473.
[13]	雷茹, 陶慧, 刘天罡. 基因组深度挖掘驱动微生物萜类化合物高效发现[J]. 合成生物学, 2024, 5(3): 507-526.
[14]	施鑫杰, 杜艺岭. 双嵌入家族抗肿瘤非核糖体肽的生物合成研究进展[J]. 合成生物学, 2024, 5(3): 593-611.
[15]	张瑞, 金文铮, 陈依军. 细菌聚酮合酶间的杂合方式及聚酮化合物生物合成逻辑[J]. 合成生物学, 2024, 5(3): 548-560.

含氨基乙烯半胱氨酸核糖体肽的生物合成与化学合成

Biosynthesis and chemical synthesis of ribosomally synthesized and post-translationally modified peptides containing aminovinyl cysteine

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 10

参考文献 68

相关文章 15

编辑推荐

Metrics

本文评价